Cannabinoid Modulation of Pain
Early Phase 1
Completed
- Conditions
- Pain
- Interventions
- Registration Number
- NCT01595620
- Lead Sponsor
- Yale University
- Brief Summary
The purpose of this study is to test the effects of cannabinoids on pain response using a variety of human experimental pain models.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
- At least one lifetime exposure to cannabis
- Acceptable Birth Control methods for females
Exclusion Criteria
- Cannabis naive
- Medical or psychiatric contraindications
- Analgesic medication
- Previous sensitivity to THC or cannabis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description THC 0.01 mg/kg Capsaicin - THC 0.01 mg/kg Thermal - THC 0.01 mg/kg Electrical - THC 0.01 mg/kg THC - Placebo Thermal - Placebo Electrical - Placebo Capsaicin - Placebo Placebo - THC 0.03 mg/kg Thermal - THC 0.03 mg/kg Electrical - THC 0.03 mg/kg Capsaicin - THC 0.03 mg/kg THC -
- Primary Outcome Measures
Name Time Method Capsaicin-induced hyperalgesia On each test day at baseline (-30), peak (+20) and post (+120) drug administration
- Secondary Outcome Measures
Name Time Method Pain Measures On each test day at baseline (-30), peak (+20) and post (+120) drug administration Non-pain subjective responses On each test day at baseline (-30), peak (+20) and post (+120) drug administration Cognitive subjective responses On each test day at baseline (-30), peak (+20) and post (+120) drug administration
Trial Locations
- Locations (1)
VA Connecticut Healthcare System
🇺🇸West Haven, Connecticut, United States